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Summary: Human (HepG2) and rat (MH1C1) hepatoblastoma cells were incubated with different concentrations of
the hypolipidaemics cetaben, clofibrate and thyroxine. The enzymatic activities of catalase, peroxisomal bifunctional
enzyme, succinate dehydrogenase, and 3-oxoacyl-CoA thiolase were measured. In order to determine the point of
regulation of the enzymatic activities Northern and Slot blot experiments with probes for peroxisomal bifunctional
enzyme, catalase and fatty acyl CoA oxidase were performed on total RNA. Catalase activity was enhanced in
HepG2 cells treated with 3 rrimol/1 clofibric acid to 135% of control and the mRNA value to 2.6 fold, whereas in
cetaben treated cells the enhancement (up to 119% of control) was less pronounced. In MH1C1 cells catalase
activity was not changed by any of the drugs. The activity of the peroxisomal bifunctional enzyme was not affected
in HepG2 cells by clofibric acid and cetaben, whereas the mRNA level was elevated to 2.3 fold by 10 μτηοΐ/l
cetaben. At high concentrations of cetaben all enzyme activities were decreased in both cell lines due to its high
cytotoxicity. Our data show that, due to the differences in the genomic organisation, the regulation of the enzyme
activities is different in human and rat, but the results from the human and rat hepatoblastoma cells correlate with
the findings in whole man and rat, so that a human in vitro system is more suitable for pharmacological tests. These
results suggest that the human hepatoma cell line HepG2 may be a useful model system for studies of the influence
of hypolipidaemics on the peroxisomal enzyme system.
Introduction (1). They contain hydrogen peroxide-producing oxidases
_ ι · . ι 11 ι 11 ι · ι like fatty acyl-CoA oxidase2) and catalase2) for the detox-Peroxisomes are ubiquitous subcellular organelles which ._ . ~' , ' / 1 N ,« . ~A,. . ^ A i: ι- " ι · ι 11 · i n location of hydrogen peroxide (1). The amount of the per-play important metabolic roles in nearly all animal cells . ι Λ. - · j i - n · ιoxisomal fraction in rodent liver cells increases several-
- »- fold upon treatment with a variety of structurally different
1 Supported by "MedizinischrWissenschaftlicher Fonds des compounds such as hypolipidaemic drugs, phthalates,
Burgerme iters der Bundeshauptstadt Wien" thyroxine and fatty acids (2). This process, known as per-
CoA oxidase, acyl-CoA : oxygen oxidoreductase (EC °xisome proliferation, increases the cellular capacity of
1.3.3.-) the -oxidation of very long-chain fatty acids by the in-
Catalase, hydrogen.peroxide : hydrogen-peroxide oxidoreductase duction of peroxisomal enzymes (2). Nevertheless, the re-
( E C 1.11.1.6) . , . · ι ι
Peroxisomal bifunctional enzyme, enoyl-CoA hydratase, and 3-hy, sPonse m human and non-human primates is much less
droxyacyl-CoA dehydrogenase (EC 4.2.1.17 and EC 1.1.1.35) pronounced than that observed in the rat and mouse (for
Succinate^dehydrogenase, succinate : (acceptor) oxidoreductase review see (3, 4)). Fibric acid derivatives are a well known
(3-oxoacyl-CoA) Thiolase, Acyl-CoA acetyl-CoA acyltransferase SrouP of hypolipidaemic drugs, mainly used for the treat-
(EC 2.3. 1.16) rnent of hyperiipidaemia in human (5).
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The model fibrate clofibric acid (2-(4-chlorophenoxy)-
2-methylpropionic acid), one of the best characterized
hypolipidaemic agents, is known to produce a profound
hepatomegalic response, including proliferation of he-
patic endoplasmic reticulum, mitochondria and peroxi-
somes after chronic treatment of rodents (6).
A different class of chemicals, lowering the concentra-
tion of lipids in blood and also noted for peroxisome
proliferative efficiency, is represented by several alkyl-
aminobenzoic acids (7). Chandoga et al. (8) have re-
ported on the effect of cetaben (sodium /?-hexadecyl
aminobenzoate), a representative of this class of non fi-
brate peroxisome proliferators, on the activities of per-
oxisomal enzymes in liver and kidney of rats, but little
is known about their effects in humans.
Like clofibrate, thyroid hormones lead to proliferation
of liver peroxisomes (9). Furthermore, thyroid hormones
increase the peroxisomal fatty acid ß-oxidation, presum-
ably by inducing acyl-CoA oxidase (10), the rate limit-
ing enzyme of this pathway (11). Various models de-
scribe the modulation of thyroid hormone action by dif-
ferential mechanisms via homo- or heterodimerization
with nuclear receptors (12).
The regulation of the induction of peroxisomal enzymes
seems to be different in different species (4, 13). In rat
a single acyl-CoA oxidase gene is present, which gives
rise to two different mRNAs by differential splicing
(14). Schepers et al. (15) identified two different fatty
acyl-CoA oxidases in rat liver, one of which is inducible
by clofibrate. Only one gene for enoyl-CoA hydratase :
3-hydroxyacyl-CoA dehydrogenase has been identified
in rat (16), which is inducible. Finally, two genes for
peroxisomal 3-oxoacyl-CoA thiolase are present in rat;
one is inducible by clofibrate (17). Thus, entirely dif-
ferent mechanisms are responsible for the induction of
individual peroxisomal ß-oxidation enzymes in rodents
by clofibrate, e. g.
(a) enhanced synthesis of a specific mRNA formed by
alternative splicing of the transcript of a single gene
(acyl-CoA oxidase), or
(b) enhanced transcription of a separate gene (thiolase),
or
(c) enhanced transcription of a single gene (enoyl-CoA
hydratase : 3-hydroxyacyl-CoA dehydrogenase) (13).
The situation in human appears to be different, as there
is only a single gene for peroxisomal 3-oxoacyl-CoA
thiolase (18), and also only one for fatty acyl-CoA oxi-
dase, with properties similar to those of the non-induc-
ible isoform in rat liver (19). This may be related to
the fact that compounds like clofibrate do not induce
peroxisomal ß-oxidation enzymes in primates (20). In
this respect it will be of interest to see if the response in
primates correlates with the response in human.
The aim of the present study was to show the difference
in the regulation of induction of peroxisomal enzymes
by peroxisomal proliferators in comparison of rats and
human. A rat and a human hepatonaa cell line, MH1C1
and HepG2, respectively, were selected as model sys-
tems. In our approach we were able to demonstrate the
differential regulation of the induction of peroxisomal
enzymes as a response to the application of hypolipidae-
mic drugs on cell cultures of human and rat liver cells.
Materials and Methods
Cell culture
HepG2 cells, derived from a human hepatoblastoma, were obtained
from the American Tissue Culture Collections (Rockville, USA)
and grown in Dulbecco's Modified Eagles Medium (GIBCO/BRL;
Paisly, UK) supplemented with foetal bovine serum (GIBCO/BRL;
Paisley, UK), volume fraction 0.1. The MH1C1 cell line, derived
from the Morris 7795 rat hepatoma, was obtained from the German
Collection of Microorganisms and Cell Cultures (Braunschweig,
Germany) and grown in Dulbecco's Modified Eagles Medium sup-
plemented with foetal bovine serum, volume fraction 0.15. All me-
dia were supplemented with 100 X 103 IU/1 penicillin G and 100
mg/1 streptomycin. The cells were kept at 37 °C in a humidified
atmosphere of 10% CO2 and 90% air (isobaric).
For all experiments cells were plated at a density of 2 106 cells
per Petri dish (diameter 100 mm) and grown to confluence. All
incubation media were prepared by adding the appropriate volume
of a stock solution of test compound. Clofibric acid (stock solution:
1 molfl) was dissolved in dimethylsulphoxide. Cetaben (25 mmol/1
stock solution) was suspended in phosphate buffered saline (8 g/1
NaCl, 0.2 g/1 KC1, 0.2 g/1 KH2PO4, 0.1 g/1 CaCl2, 0.1 g/1 MgCl2
• 6H2O, 2.9 g/1 Na2HPO4 · 12H20, pH = 7.2).
Triiodothyronine (50 mmol/1 stock solution) was prepared in 0.01
mol/1 NaOH. Incubation media were sonicated for 10 min at room
temperature before use. Treatment of the confluent monolayers was
commenced by replacing the culture media with incubation media
supplemented with the test compounds. Incubations were carried
out for 24 hours. The monolayers were washed two times with
phosphate buffered saline. The cells were detached by means of
trypsin-EDTA (0.5 g/1 trypsin, 0.2 g/1 EDTA) for 5 min at 37 °C.
Cell suspensions were sedimented for 5 min at 300 g, resuspended,
centrifuged again and suspended in ice cold phosphate buffered sa-
line.
Enzyme assays
For the determination of catalase activity, cells were incubated with
10 g/1 Triton X-100 for 2 min prior to the assay.
For the determination of enzyme activities, cells were homogenised
with a Potter homogeniser for l min at 1000 min"1 at 0 °C.
Succinate dehydrogenase was determined according to Kremser et
al. (21). Enoyl-CoA hydratase : 3-hydroxyacyl Co A dehydrogenase
(peroxisomal bifunctional enzyme) was estimated by measuring the
crotonoyl-CoA dependent formation of NADH at 340 nm (22)·.
The assay of thiolase was performed by measuring the thioester
absorption band at 233 nm using acetoacetyl-CoA as a substrate
(23). cCatalase was assayed according to Baudhuin et al. (24). The
protein content in cell homogenates was measured according to the
method of Bradford (25) using the -Rad protein assay kit (Bio-
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Rad, Hercules, USA). All specific activities are expressed as mU/
mg protein.
Preparation of RNA
Total cellular RNA was prepared according to the method de-
scribed by Sambrook et al. (26) from confluent HepG2 and MH1CI
cells treated with the substances indicated. The RNA content was
estimated by measuring the absorbance at 260 nm. Total RNA was
precipitated with ethanol and stored at —70 °C.
Poly (A+) RNA was isolated using the PolyATtract mRNA isola-
tion system III of Promega according to the manufacturer's instruc-
tions (Promega; Madison, USA).
Northern- and slot-blot analysis
RNA was separated by electrophoresis on 1% agarose gels under
denaturing conditions and then transferred to Hybond-N mem-
branes (Amersham; Little Chalfont, UK) by capillary blotting tech-
nique (26). RNA molecular weight marker II (Boehringer Mann-
heim; Mannheim, Germany) was used as size standard in RNA gel
electrophoresis.
For slot-blot analysis total RNA was denatured with formaldehyde
and applied to Hybond-N membranes. RNA was fixed to the mem-
branes by UV-crosslinking. The probes used in the hybridisation
procedures included restriction fragments of Pstl fragment of rat
acyl CoA oxidase (686 bases) (27), Xbal fragment of human enoyl-
CoA hydratase : 3-hydroxyacyl-CoA dehydrogenase (1 X 103
bases) (28), EcoRl fragment of human catalase (2.2 Χ 103 bases,
personal communication; Prof. /. Singh), Pstl fragment of rat cata-
lase (1 Χ 103 bases) (29), EcoRI fragment of human -actin (1.1
Χ ΙΟ3 bases) (30) and Pstl fragment of mouse -actin (1.1 Χ ΙΟ3
bases) (31).
cDNA probes were labelled with [a-32P]dCTP using the NEBlot
Kit (New England Biolabs; Beverly, USA) (32). Membranes were
prehybridised in a solution containing 500 g/1 formamide, 0.75
mol/1 NaCl, 75 mmol/1 sodium citrate (pH = 7), 0.4 g/1 Ficoll 400,
0.4 g/1 polyvinylpyrrolidone, 0.4 g/1 bovine serum albumin (Frac-
tion V), 1 g/1 SDS, 200 mg/1 salmon sperm DNA and 100 g/1
dextran sulphate at 42 °C for 2 h and after addition of the denatured
probes hybridisation was carried out overnight. Membranes were
washed twice for 15 min in 0.3 mol/1 NaCl, 30 mmol/1 sodium
citrate (pH = 7), 1 g/1 SDS, at room temperature, followed by two
washes for 15 min at 42 °C in 0.15 mol/1 NaCl, 15 mmol/1 sodium
citrate (pH =7), 1 g/1 SDS. Membranes were autoradiographed
using Kodak X-Omat films and intensifying screens (Kodak; Roch-
ester, USA).
After autoradiography, the RNA filters were washed using 0.005
moVl Tris-HCl (pH 8.0), 0.002 mol/1 EDTA and 0.02 g/1 Ficoll
400, 0.02 g/1 polyvinylpyrrolidone, 0.02 g/1 bovine serum albumin
(Fraction V), 0.05 g/1 SDS for 2 h at 65 °C and reprobed. Mem-
branes treated this way revealed no signs of diminished quality
after reprobing. Human and mouse -actin cDNA were used to
rehybridise the membranes and served as an internal standard for
the normalisation of the RNA levels. Slot blots were quantified
by counting each blot with the Instantlmager {Canberra Packard;
Meriden, USA), and densitometry was performed using the Phar-
macia Image Master (Pharmacia; Uppsala, Sweden).
Cytotoxicity assay
Cytotoxicity was assessed by measurement of the activity of mito-
chondrial dehydrogenases of viable cells (33). Cells were seeded
on 1ml microtitration plates at cell densities of 10 X 106/1, 50
X 106/1, and 100 X 106/1. Twentyfour hours after plating cells were
treated with the test compounds for 24 hours. 3-(4,5-Dimethylthia-
zol-2-yl)-2,5-diphenyl-tetrazolium bromide (MTT) was added di^·
rectly to the wells. After 3 hours at 37 °C media was removed, the
formazan was solubilized in dimethylsulphoxide/acetic acid/SDS
(100 g/1 SDS, 100 mmol/1 acetic acid in dimethylsulphoxide) and
the plates were read on a Microplate Autoreader (Bio-Tek Instru-
ments, Winooski, USA) at 570 nm. The formazan is produced pro-
portional to the dehydrogenase activity.
Morphology
After treatment with the test compound cells were harvested and
washed twice with ice-cold phosphate buffered saline and fixed in
ice-cold glutaraldehyde (25 g/1) in 0.2 mol/1 phosphate buffer, pH
7.2. After 3 hours of fixation the cells were washed with phosphate
buffered saline and postfixation with 1% osmium tetroxide was
employed. The specimens were washed in distilled water, dehy-
drated in a series of graded ethanol solutions and routinely embed-
ded in Epon 812. Ultrathin section were cut with an ultramicrotome
(Reichert, Vienna, Austria) and examined in a Zeiss EM9S/2
electron microscope (Zeiss, Oberkochen, Germany).
Statistics
Statistical comparison between the control groups and the treated




Electron microscopical comparisons of hepatoma cell
lines (treated and untreated) were carried out to confirm
proliferation by the application of clofibric acid. HepG2
cells presented inconspicuously. They were provided
with abundant free ribosomes, contained short segments
of rough endoplasmic reticulum, Golgi areas and cristae-
type mitochondria (fig. 1). Peroxisomes were rarely
identified. These organelles were mostly oval in shape
Fig. 1 Electron micrographs showing peroxisomes in HepG2
cells, control preparation with dimethylsulphoxide. Cells contain
abundant ribosomes, segments of rough endoplasmic reticulum,
Golgi regions, mitochondria, and a few lipid droplets. Microbodies
are rarely seen (inserts); they represent microperoxisomes with
granular matrix but without a crystalline core. Magnification:
X 1900; insert X 8900.
Eur J Clin Chem din Biochem 1995; 33 (No 11)
778 Staiigl et al.: Modulation of peroxisomal enzymes by hypolipidaemics.
and measured 0.2-0.25 μιη in diameter. They contained
granular matrix material of moderate electron density
and were confined by a single membrane (fig. 1, in-
serts). After treatment with clofibric acid, the number of
microperoxisomal profiles was increased but morphol-
ogy and size of the individual organelles appeared un-
changed (fig. 2).
Comparable results were obtained with the rat hepatoma
cell line MH1C1 (results not shown).
Cytotoxicity
The toxicological effects of the compounds used were
verified by measurement of the mitochondrial dehydro-
genases of the cells in order to estimate the concentra-
Fig. 2 Electron micrographs showing peroxisomes in HepG2
cells, cells treated with 3 mmol/1 clofibric acid. Gross morphology
of HepG2 cells closely resembles that of control cells (compare
with fig. 1). The number of microperoxisomes, however, is
increased (encircled regions; two of them are shown at higher mag-
nification in the inserts). Note that mitochondrial volume also ap-
pears slightly enlarged. Magnification: X 1900; insert X 8900.
tion range of cytotoxicity, because toxicological effects
need to be avoided for proliferation experiments. The
results of the cytotoxicity assays indicate that clofibric
acid and triiodothyronine do not influence the viability
of both cell lines at concentrations below 5 mmol/1 and
100 μηιοΙ/1, respectively (data not shown). Cetaben
treated cells already show a significant response at 10
μιηοΐ/ΐ. The fractional survivals of HepG2 and MH1C1
cell lines at a number of 100000 cells per well treated
with 100 μιηοΐ/ΐ cetaben were 66% and 45% of control
(p < 0.001) respectively (fig. 3: Α-B). The cytotoxic
effect was more pronounced at a cell number of 10000,
where the fractional survival for both cell lines was 37%
(p < 0.001). The rat hepatoma cell line showed a greater
sensitivity at higher cell number towards cetaben than
the human cell line (fig. 3: Α-B). Since cytotoxicity
was lower at higher cell densities confluent monolayers
were used for all experiments. These findings agree with
previous morphological studies on rat hepatocytes (34).
Enzymes
In order to quantify the difference of the induction of
peroxisomal proliferation between human (HepG2) and
rat (MH1C1) cells, peroxisomal and mitochondrial en-
zymatic activities were determined.
In HepG2 3 mmol/1 clofibric acid had no effect on thio-
lase and the peroxisomal bifunctional enzyme activities.
The activity of catalase was increased from 19.9 ±2.1
to 26.7 ± 2.7 mU/mg (p < 0.01), succinate dehydroge-
nase activity from 13.5 ± 0.7 to 18 ± 2.5 mU/mg by
3 mmol/1 clofibric acid (see tab. 1A). Catalase activity
was increased by 10 μπιοΐ/ΐ and 100 μπιοΐ/ΐ cetaben to
about 120% of control (p < 0.01; control activity: 17.7
± 1.2 mU/mg), whereas the peroxisomal bifunctional
enzyme was not affected (control activity: 37.9 ± 4.4
mU/mg). Ten μτηοΐ/ΐ cetaben did not alter the activity
1 10 50
Concentration of Cetaben U/mol/1]
100
Fig. 3A-B Comparison of the dose response of HepG2 and
MH1C1 cell lines at different concentrations of cetaben.
Fractional survival of HepG2 (Panel A) and MH1C1 (Panel B)
using the cytotoxicity assay (see Method's section). Filled circles:
Β
1 10 50
Concentration of Cetaben Uimol/l]
100
cell number = 100.000; open circles: cell number = 50.000; open
triangles: cell number = 10.000. All experiments were performed
in triplicate.
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of succinate dehydrogenase, whereas the activity was
decreased by 100 μιηοΐ/ΐ cetaben from 11.8 ± 1.0 to 8,7
± 1.4 mU/mg (p < 0.01). Thiolase activity was slightly
Tab. 1 Relative specific activities of catalase, the peroxisomal bi-
functional enzyme, succinate dehydrogenase and thiolase of
HepG2 (Panel A) and MH1C1 (Panel B) cells after treatment for




































































The values are given as % of control ± %SEM. *p<0.01;
** ρ < 0.02; η indicates the number of experiments. The specific
activities are given in the result section.
enhanced by 10 μηαοΐ/ΐ cetaben from 319.5 ±43.6 to
379.3 ± 30.1 mU/mg, but 100 μΐΏθΙ/l cetaben slightly
decreased the activity to 283.6 ± 35 πιο/mg (tab. 1A).
In HepG2 cells the activities of all enzymes were not
affected by treatment with 10 μπιοΐ/ΐ and 100 μηιοΐ/ΐ
triiodothyronine (data not shown).
Three mmol/1 clofibric acid did not increase the activi-
ties of catalase (control activity 71.1 ±1.9 mU/mg),
succinate dehydrogenase (control activity 7.1 ± 2.5 mil/
mg) and the peroxisomal bifunctional enzyme (control
activity 52.9 ±5.4 mU/mg) in MH1C1 cells, whereas
thiolase activity was enhanced from 166.5 ±21.9 to
207.6 ± 12.5 mU/mg (tab. IB). The mitochondria!
marker succinate dehydrogenase was decreased by 10
μιυοί/ΐ cetaben from 8.9 ± 1.2 to 6.7 ± 0.7 mU/mg and
further significantly decreased by 100 μιηοΐ/ΐ cetaben to
5.1 ± 0.8 mU/mg (p < 0.01) in MH1C1. Thiolase activ-
ity was enhanced by 10 μπιοΐ/ΐ and 100 μηιοΙ/1 cetaben
from 172.4 ± 8.2 to 222.2 ± 18.6 mU/mg (p < 0.02)
and to 212.8 ± 30.1 mU/mg. Catalase and the peroxi-
somal bifunctional enzyme showed no response to the
treatment with cetaben in MH1C1 cells (tab. IB). The
activities of all enzymes were not significantly affected
by treatment with 10 μηιοΐ/ΐ and 100 μηιοΐ/ΐ triiodothy-
ronine in MH1C1 cells (data not shown).
RNA analysis
Northern blot experiments with mRNA of HepG2 (fig.
4) and MH1C1 (fig. 5) were carried out to confirm the
identity of the probes.
In order to determine whether the observed variations in
catalase, peroxisomal bifunctional enzyme and acyl-






Fig. 4 Northern blot analysis of HepG2 cells after hybridisation
with a cDNA probe for human -actin (panel A), a cDNA probe
for human catalase (panel B) and a probe derived from the human
peroxisomal bifunctional enzyme cDNA (panel C). RNA size
marker is indicated on the left. The mRNA sizes are: -actin 2.1
Χ ΙΟ3 bases, catalase 2.7 Χ 103 bases and peroxisomal bifunc-







Fig. 5 Northern blot analysis of MH1C1 cells after hybridisation
with a cDNA probe for mouse -actin (panel A), a cDN A probe
for rat catalase (panel B) and a cDNA probe for rat fatty acyl-CoA
oxidase (panel C). RNA size marker is indicated on the left. The
mRNA sizes are: catalase 2.8 Χ 103 bases, fatty acyl-CoA oxidase
4.2 X 103 bases and -actin 2.2 Χ ΙΟ3 bases.
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sion of the corresponding genes, we determined the cel-
lular mRNA levels after 24 hours of incubation of
HepG2 and MH1C1 cells with 3 mmol/1 clofibric acid,
10 μιηοΐ/ΐ and 100 μηιοΐ/ΐ cetaben with different
amounts of RNA. Cell monolayers from the correspond-
ing subcultures, which were used for determination of
enzyme activities or cytotoxicity assays, were incubated
in parallel in Dtdbecco's Modified Eagles medium with
or without peroxisomal proliferators. mRNA levels were
assayed by slot-blotting, using specific 32P-labelled
probes (fig. 6, 7 and 8), as described in Materials and
Methods. The -actin mRNA level was used as an in-
ternal standard.
1 2 3 4 5 6
Lane 1 M i l
A
B
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Lonel θ 0 I 0 0 I
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Fig. 6 Slot blot analysis of the effect of clofibric acid on catalase
in HepG2 cells. HepG2 cells were exposed to 3 mmol/1 clofibric
acid for 24 h. Total RNA was purified, denatured and applied to
the membrane (slots 1, 4: 20 μ& slots 2, 5: 10 μg; slots 3, 6: 1 μ^
lane 1: control cells; lane 2: 3 mmol/1 clofibric acid). The mem-
brane was hybridised with 32P-labelled cDNAs for catalase (panel
A), washed and rehybridised with a probe for -actin (panel B).
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Fig. 7 Slot blot analysis of the effect of cetaben on the peroxidase
biftmctional enzyme in HepG2 cells. HepG2 cells were exposed to
10 μπιοΙ/1 (slots 1, 2, 3) and 100 μιηοΐ/ΐ (slots 4, 5, 6) cetaben
for 24 h. Total RNA was purified, denatured and applied to the
membrane; lane 1: control cells (slot 1: 20 μ§; slot 2: 10 μ§; slot
3: 1 μg); lane 2: Cetaben (slots 1, 4: 20 μ& slots 2, 5: 10 μ^ slots
3, 6: 1 μg). The membrane was hybridised with 32P-labelled
cDNAs for peroxisomal bifiinctional enzyme (panel A), washed
and rehybridised with a probe for -actin (panel B).
As shown in table 2 catalase mRNA was 2.6 fold higher
in HepG2 cells treated with 3 mmol/1 clofibric acid than
in controls (p < 0.001). The significant increase of
mRNA levels induced by clofibric acid also correlates
with the higher activity of catalase (tab. 1). Interestingly
the mRNA levels of the peroxisomal bifiinctional en-











Fig. 8 Slot blot analysis of the effect of clofibric acid on fatty
acyl-CoA oxidase in MH1C1 cells. MH1C1 cells were exposed to
3 mmol/1 clofibric acid for 24 h. Total RNA was purified, dena-
tured and applied to the membrane (slot 1: 20 μ§; slot 2: 10 μ§;
slot 3: 1 μ§; lane 1: control cells; lane 2: 3 mmol/1 clofibric acid).
The membrane was hybridised with 32P-labelled cDNAs for fatty
acyl-CoA oxidase (panel A), washed and rehybridised with a probe
for -actin (panel B).
Tab. 2 Relative mRNA levels of catalase and the peroxisomal
bifunctional enzyme in HepG2 cells and of catalase and fatty acyl-
CoA oxidase mRNAs in MH1C1 cells after treatment for 24 h.


























After autoradiography, the densities were recorded and expressed
in conventional densitometric units to calculate the relative levels.
Each value was divided by the corresponding mRNA -actin value.
Finally, the relative levels of mRNA in treated cells were divided
by the relative values of parallel non-treated control cells. The ra-
tios are given as mean ± SEM; n = 3; * p < 0.01, ** p < 0.001
as compared with the corresponding control value.
Eur J Clin Chem Clin Bioehem 1995; 33 (No 11)
Stangl et al.: Modulation of peroxisomal enzymes by hypolipidaemics 781
which correlates well with the enzyme activities in
HepG2 (tab. 1).
The mRNA level for the peroxisomal bifunctional en-
zyme in HepG2 cells treated with 10 μιηοΐ/ΐ cetaben
was elevated significantly to 2.3 fold as compared
with the control (p<0.01), whereas treatment with
100 μιηοΐ/ΐ cetaben did not cause a significant
increase. These findings do not correlate with the en-
zymatic activities of the peroxisomal bifunctional en-
zyme which remained unchanged at all concentrations
of cetaben.
The mRNA for fatty acyl-CoA oxidase of MH1C1 cells
was increased 1.8 fold (p < 0.001) by 3 mmol/1 clofibric
acid which correlates well with the findings of Than-
gada et al. (34) using Ciprofibrate in primary hepatocyte
cultures. Cetaben treated cells showed a similar increase
in fatty acyl-CoA oxidase (2.4 fold, p < 0.01) using 100
μιηοΐ/ΐ cetaben (tab. 2).
Catalase mRNA was not affected by 3 mmol/1 clofibric
acid (tab. 2) which parallels the enzymatic activity.
Discussion
The main objective of the present study was to show
the difference in the regulation of the peroxisomal β-
oxidation of a human (HepG2) and rat (MH1C1) cell
line. In order to elucidate if the effects on the peroxi-
somal -oxidation are correlated with the cytotoxicity of
the chemicals a cytotoxicity assay was carried out. This
assay indicates that clofibric acid and triiodothyronine
at concentration of 5 mmol/1 and 100 μιηοΐ/ΐ, respec-
tively, are not toxic, whereas cetaben is highly toxic
even at low concentrations (100 μιηοΐ/ΐ). Therefore the
effects of higher concentrations of cetaben on the per-
oxisomal -oxidation are superimposed by its cytotoxic-
ity. Succinate dehydrogenase, a mitochondrial marker
enzyme, was used to check the status of the mito-
chondrial energy producing system to verify the energy
state of the cells. Clofibric acid enhances succinate de-
hydrogenase whereas cetaben, due to its cytotoxicity,
significantly decreases its activity (see tab. 1). This dif-
ferential effect is more pronounced in MH1C1 cells in-
dicating that rat cells are more sensitive to peroxisomal
proliferators. On the other hand the activity of catalase,
a peroxisomal marker, is increased in HepG2 cells by
cetaben and clofibric acid, which is caused by a much
higher response of mRNA synthesis (see tab. 1 and 2),
and additionally the response of mRNA by clofibric acid
treated cells is much higher than the increase in activity.
Moreover the activities of the peroxisomal bifunctional
enzyme in both cell lines are unaffected, although the
mRNA level was enhanced to 2.3 fold by 10 μιηοΐ/ΐ
cetaben in HepG2 cells. In order to elucidate whether
the increase of the activities of peroxisomal enzymes in
hepatoma cell lines is weaker than in primary hepato-
cytes (34) or whether the increase is delayed, as sug-
gested by the higher mRNA levels, long term studies
have to be carried out.
It seems that the proliferation of the peroxisomal
bifunctional enzyme is more pronounced if compared
to other enzymes like succinate dehydrogenase (at
10 μπιοΐ/ΐ cetaben enzyme activity is 75% of control).
Interestingly the response of thiolase to clofibric acid
and cetaben is higher in MH1C1 cells whereas the
response in HepG2 varies. The decrease of the activity
of thiolase at 100 μιηοΐ/ΐ cetaben seems to be due to
the high cytotoxicity. Cetaben also increases the activ-
ity of the peroxisomal -oxidation system but this
effect is compensated by the cytotoxicity of the com-
pound.
At the concentrations used triiodothyronine does not
trigger any response at all, which can be explained by
the difference in the receptor mediated response (12).
The effect of hypolipidaemic drugs seen in our cell
model is less pronounced than in rat liver but stronger
in the rat cell line MH1C1 than in the human cell line
HepG2, but is in accordance with previous findings of
Graham et al. (20) in primates and of Hanefeld et al.
(35) in humans which indicates that the peroxisomal
proliferation in human and primate is not as pronounced
as in rat, although the lipid lowering effect is present in
human (5). The hypotriglyceridaemic action of the se
drugs is reported to be due to the decrease of apolipo-
protein C-III gene expression, which was demonstrated
by Staels et al. (36) in rat and human hepatocytes.
Therefore this weak response of HepG2 to peroxisomal
proliferators is in accordance with the assumed effect in
human liver in vivo. Similar findings using human and
rat hepatic cell lines have been previously reported by
Scotto et al. (37) using clofibrate and Brocard et al. (38)
using ciprofibrate.
Our results indicate that the human hepatoma cell line
HepG2, as previously indicated by Watkins et al. (39),
is an appropriate model for studies of the influence of
hypolipidaemic agents on the peroxisomal enzyme sys-
tem.
Acknowledgements
The authors would like to thank Ms. Maria Pedru for excellent
technical assistance. Cetaben was kindly provided by American
Cyanamid Company, Lederle Laboratories Division, Pearl River,
USA. The cDNA for the rat acyl-CoA oxidase was a gracious gift
from Prof. T. Oswni> the cDNA for the rat catalase was kindly
Eur J Clin Chem Clin Biochem 1995; 33 (No 11)
782 Stangl et al.: Modulation of peroxisomal enzymes by hypolipidaemics.
provided by Dr. S. Fwuta. The authors would like to thank Dr. G.
Höfler for his generous gift of cDNA for the human peroxisomal
birunctional enzyme. The cDNA for human catalase was donated
by Prof. /. Singh.
References
1. Lazarow PB, Fujiki F. Biogenesis of peroxisomes. Ann Rev
CellBiol 1985; 1:489-530.
2. Kramar R. Die Beteiligung der Peroxisomen am LipidstofF-
wechsel. J Clin Chem Clin Biochem 1986; 24:109-18.
3. Reddy JK, Mannaerts GP. Peroxisomal lipid metabolism. Annu
RevNutr 1994; 14:343-70.
4. Sirtori CR, Galli C, Franceschini G. Fraudulent (and non
fraudulent) fatty acids for human health. Eur J Clin Invest
1993; 23:686-9.
5. Sirtori CR, Manzoni C, Lovati MR. Mechanisms of lipid-
lowering agents. Cardiology 1991; 78:226-35.
6. Hawkins JM, Jones WE, Bonner FW, Gibson GG. The effect
of peroxisome proliferators on microsomal, peroxisomal, and
mitochondrial enzyme activities in the liver and kidney. Drug
Metabol Rev 1987; 18:441-515.
7. Fort FL, Stein HH, Langenberg K, Lewkowski JP, Heyman IA,
Kesterson J W. Cetaben versus clofibrate comparison of toxic-
ity and peroxisome proliferation in rats. Toxicology 1983;
28:305-11.
8. Chandoga J, Hampl L, Turecky L, Rojekova I, Uhlikova E,
Hocman G.. Cetaben is an exceptional type of peroxisome pro-
liferator. Int J Biochem 1994; 26:679-96.
9. Just WW, Hartl FU, Schimassek H. Rat liver peroxisomes. I.
New peroxisome population induced by thyroid hormones in
the liver of male rats. Eur J Cell Biol 1982; 26:249-54.
10. Kramar R, Kremser K, Hohenegger M, Mayer M. Fatty acyl-
CoA oxidase in rat kidney and liver after application of thyrox-
ine. Enzyme 1986; 35:27-33.
11. Hryb DJ, Hoff JF. Chain length specificities of perpxisomal
and mitochondrial ß-oxidation in rat liver. Biochem Biophys
Res Comm 1979; 87:1200-6.
12. Meier-Heusler SC, Zhu X, Juge-Aubry C, Pernin A, Burger
AG,% Cheng SY, Meier CA. Modulation of thyroid hormone
action by mutant thyroid hormone receptors, c-erbAa2 and
peroxisome proliferator-activated receptor: evidence for dif-
ferent mechanisms of inhibition. Mol Cell Endocrinol 1995;
107:55-66.
13. Van den Bosch H, Schutgens RBH, Wanders RJA, Tager JM.
Biochemistry of peroxisomes. Annu Rev Biochem 1992;
61:157-97.
14. Osumi T, Ishii N, Miyazawa S, Hashimoto T. Isolation and
structural characterization of the rat acyl-CoA oxidase gene. J
Biol Chem 1987; 262:8138-43.
15. Schepers L, Van Veldhoven PP, Casteels M, Eyssen HJ,
Mannaerts GP. Presence of three acyl-CoA oxidases in rat
liver peroxisomes. An inducible fatty acyl-CoA oxidase, a
noninducible fatty acyl-CoA oxidase, and a noninducible
trihydroxycoprostanoyl-CoA oxidase. J Biol Chem 1990;
265:5242-6.
16. Ishii N, Hijikata M, Osumi T, Hashimoto T. Structural organ-
ization of the gene for rat enoyl-CoA hydratase: 3-hydroxy-
acyl-CoA dehydrogenase birunctional enzyme. J Biol Chem
1987; 262:8144-50.
17. Hijikata M, Wen JK, Osumi T, Hashimoto T. Rat peroxisomal
3-ketoacyl-CoA thiolase gene. Occurrence of two closely re-
lated but differentially regulated genes. J Biol Chem 1990;
265:4600-6.
18. Bout A, Franse MM, Collins J, Blonden L, Tager JM, Benne
R. Characterization of the gene encoding human peroxisomal
3-oxoacyl-CoA thiolase (ACAA). No large DNA rearrange-
ment in a thiolase-deficient patient. Biochim Biophys Acta
1991; 1090:43-51.
19. Casteels M, Schepers L, Van Veldhoven P, Eyssen HJ, Man-
naerts GP. Separate peroxisomal oxidases for fatty acyl-CoAs
and trihydroxycoprostanoyl-CoA in human liver. J Lipid Res
1990; 31:1865-72.
20. Graham MJ, Wilson SA, Winham MA, Spencer AJ, Rees JA,
Old SL, et al. Lack of peroxisome proliferation in marmorset
liver following treatment with ciprofibrate for 3 years. Fundam
Appl Toxicol 1994; 22:58-64.
21. Kremser K, Schön HJ, Lohninger A, Prager CM, Kramar R,
Bock P. Response to thyroxine of lamellar bodies, peroxisomes
and peroxisomal enzymes in the adult rat lung. Eur J Clin
Chem Clin Biochem 1991; 29:151-8.
22. Lazarow PB. Different chain length specificities of peroxi-
somal and mitochondrial enoyl-CoA hydratases. Arch Bio-
chem Biophys 1981; 206:342-5.
23. Lazarow PB. Rat liver peroxisomes catalyze the ß-oxidation
of fatty acids. J Biol Chem 1978; 253:1522-8.
24. Baudhuin P, Beaufay H, Rahman-Li Y, Sellinger OZ, Wattiqux
R, Jacques P, et al. Tissue fractionation studies: intracellular
distribution of monoamine oxidase, aspartate aminotransfer-
ase, alanine aminotransferase, D-amino acid oxidase and cata-
lase in rat-liver tissue. Biochem J 1964; 92:169-84.
25. Bradford M. A rapid and sensitive method for the quantitation
of microgram quantities of protein utilizing the principle of
protein dye binding. Anal Biochem 1976; 72:248-54.
26. Sambrook J, Fritsch EF, Maniatis T. Molecular cloning. A lab-
oratory manual. 2nd ed. Cold Spring Habor, New York: Cold
Spring Harbor Laboratory, 1989.
27. Miyazawa S, Osumi T, Hashimoto T, Ohno K, Miura S, Sujiki
Y. Peroxisome targeting signal of rat liver acyl-coenzyme A
oxidase resides at the carboxy terminus. Mol Cell Biol 1989;
9:83-91.
28. Hoefler G, Forstner M, McGuinness MC, Hulla W, Hiden M,
Krisper P, et al. cDNA cloning of the human peroxisomal en-
oyl-CoA hydratase : 3-Hydroxyacyl-CoA dehydrogenase bi-
functional enzyme and localization to chromosome 3q26.3-
3q28: a free left Alu arm is inserted in the 3'noncoding region.
Genomics 1994; 19:60-7.
29. Furuta S, Hayashi H, Hijikata M, Miyazawa S, Osumi T, Has-
himoto T. Complete nucleotide sequence of cDNA and de-
duced amino acid sequence of rat liver catalase. Proc Natl
Acad Sei USA 1986; 83:313-7.
30. Adams MD, Kelley JM, Gocayne JD, Dübnick M, Polymero-
poulos MH, Xiao H, et al. Complementary DNA sequencing:
expressed sequence tags and human genome project. Science
1991; 252:1651-6.
31. Minty AJ, Alonso S, Guenet JL, Buckingham ME. Number of
organization of actin-related sequences in the mouse genome.
J Mol Biol 1983; 167:77-101.
32. Feinberg AP, Vogelstein B. A technique for radiolabelling
DNA restriction endonuclease fragments to high specificity.
Anal Biochem 1983; 132:6-13.
33. Mossman T. Rapid colorimetric assay for cellular growth and
survival: application to proliferation and cytotoxicity assays. J
Immunol Mem 1983; 65:55-63.
34. Thangada S, Alvares K, Mangino M, Usman MI, JRao MS,
Reddy JK. An in vitro demonstration of peroxisomes prolifera-
tion and increase in peroxisomal ß-oxidation system mRNAs
in cultured rat hepatocytes treated with ciprofibrate. FEBS Let-
ters 1989; 250:205-10.
35. Hanefeld M, Kemmer C, Kadner E. Relationship between mor-
phological changes and lipid-lowering action of p-chlorphe^
noxyisobutyric acid (CPIB) on hepatic mitochondria and per-
oxisomes in man. Atheriosclerosis 1983; 46:239-46.
36. Staels B, Vu-Dac N, Kosykh VA, SaladhvR, Fruchart JC, Dal-
longeville J, Auwerx J. Fibrates downregulate apolipoprotein
C-III expression independent of induction of peroxisomal acyl
coenzyme A oxidase. J Clin invest 1995; 95:705-12.
37. Scotto C, Keller JM, Schohn H, Dauca M. Comparative effects
of elofibrate on peroxisomal enzymes of human (Hep EBNA2)
Eur J Clin Chem Clin Biochem 1995; 33 (No 11)
Stangl et al.: Modulation of peroxisomal enzymes by hypolipidaemics 783
and rat (FaO) hepatoma cell lines. Eur J Cell Biol 1995; 39. Watkins PA, Ferrell EV, Pedersen JI, Hoefler G. Peroxisomal
66:375-81. fatty acid ß-oxidation in HepG2 cells. Arch Biochem Biophys
38. Brocard C, Es-Souni M, Ramirez LC. Latruffe N, Boumot P. 1991; 289:329-36.
Stimulation of peroxisomal palmitoyl-CoA oxidase activity by
ciprofibrate in hepatic cell lines: comparative studies in Fao, Dr. Karl Kremser





Eur J Clin Chem Clin Biochem 1995; 33 (No 11)

